PSGL-1 blockade delays relapse to BRAF/MEK inhibition in cutaneous melanoma
Olivia S. El Naggar, Binh N. Ha, Mahary Lalarizo Rakoto, Laura Cort, Amirali Amirfallah, Elizabeth A. Haglund, Pedro Urquiza, Hannah A. F. Hetrick, Linda M. Bradley, Edward J. Hartsough, Jennifer L. Hope, Gabriele Romano
This study shows that blocking PSGL-1 with BRAF/MEK inhibition improves durable tumor control in melanoma by reprogramming CD8+ T cells to a memory-like state.
bioRxiv · Jul 7, 2026 · PreprintImmunology